Cannabinoid Receptor Ligands and Idiopathic Pulmonary Fibrosis
Author Information
Author(s): KÖSE Sevil, ÖNEN Selin, GİZER Merve, BODUROĞLU Esin, GÖNÜLLÜ Uğur, KORKUSUZ Petek
Primary Institution: Akdeniz University
Hypothesis
Cannabinoids, known for their antifibrotic and inflammation-modulating effects, might effectively treat idiopathic pulmonary fibrosis (IPF).
Conclusion
CB signaling regulates the progression of pulmonary inflammation and fibrosis via CBR activation, suggesting potential pharmacological tools for antifibrosis therapies.
Supporting Evidence
- LL24, LL29, A549, and THP-1 cells exhibited CB1 and CB2 receptors.
- CB1R and CB2R agonists inhibited fibroblastic and epithelial cell proliferation.
- TGF-β1 and TNF-α release increased, while IL-8 release decreased in response to cannabinoid treatment.
- CB2R agonist JWH015 decreased collagen Type I expression in IPF lung fibroblasts.
Takeaway
This study found that certain compounds from cannabis can help reduce inflammation and scarring in the lungs, which could be useful for treating a serious lung disease.
Methodology
The study used flow cytometry to detect cannabinoid receptors and ELISA to measure inflammatory cytokines in various cell types.
Limitations
The study is limited to in vitro findings and needs confirmation through in vivo studies.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website